Cargando…

microRNA‐99a‐5p induces cellular senescence in gemcitabine‐resistant bladder cancer by targeting SMARCD1

Patients with advanced bladder cancer are generally treated with a combination of chemotherapeutics, including gemcitabine, but the effect is limited due to acquisition of drug resistance. Thus, in this study, we investigated the mechanism of gemcitabine resistance. First, gemcitabine‐resistant cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamai, Motoki, Tatarano, Shuichi, Okamura, Shunsuke, Fukumoto, Wataru, Kawakami, Issei, Osako, Yoichi, Sakaguchi, Takashi, Sugita, Satoshi, Yonemori, Masaya, Yamada, Yasutoshi, Nakagawa, Masayuki, Enokida, Hideki, Yoshino, Hirofumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936529/ https://www.ncbi.nlm.nih.gov/pubmed/35148461 http://dx.doi.org/10.1002/1878-0261.13192

Ejemplares similares

Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor
por: Yoshino, Hirofumi, et al.
Publicado: (2023)

EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer
por: Okamura, Shunsuke, et al.
Publicado: (2021)

Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation
por: Yoshino, Hirofumi, et al.
Publicado: (2020)

Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant
por: Tsuruda, Masafumi, et al.
Publicado: (2020)

Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
por: Kuroshima, Kazuki, et al.
Publicado: (2020)

Potential therapeutic target secretogranin II might cooperate with hypoxia‐inducible factor 1α in sunitinib‐resistant renal cell carcinoma
por: Fukumoto, Wataru, et al.
Publicado: (2023)

Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma
por: Yoshino, Hirofumi, et al.
Publicado: (2020)

Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery
por: Tatarano, Shuichi, et al.
Publicado: (2021)

Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer
por: Sakaguchi, Takashi, et al.
Publicado: (2017)

Laparoscopic Surgery for Pheochromocytoma in Hemodialysis Patients
por: Tatarano, Shuichi, et al.
Publicado: (2022)

Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma
por: Yoshino, Hirofumi, et al.
Publicado: (2017)

Low dose tacrolimus exposure and early steroid withdrawal with strict body weight control can improve post kidney transplant glucose tolerance in Japanese patients
por: Mitsuke, Akihiko, et al.
Publicado: (2023)

Kidney transplantation with concomitant simple nephrectomy by thoracoabdominal approach for patients with huge autosomal dominant polycystic kidney disease (ADPKD): A case report
por: Yamada, Yasutoshi, et al.
Publicado: (2019)

Dual tumor‐suppressors miR‐139‐5p and miR‐139‐3p targeting matrix metalloprotease 11 in bladder cancer
por: Yonemori, Masaya, et al.
Publicado: (2016)

Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines
por: TATARANO, SHUICHI, et al.
Publicado: (2011)

The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer
por: Yoshino, H, et al.
Publicado: (2011)

Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): inhibition of bladder cancer cell aggressiveness
por: Matsushita, Ryosuke, et al.
Publicado: (2016)

SMARCD1 regulates senescence-associated lipid accumulation in hepatocytes
por: Inoue, Chisato, et al.
Publicado: (2017)

LncRNA SMARCD3-OT1 Promotes Muscle Hypertrophy and Fast-Twitch Fiber Transformation via Enhancing SMARCD3X4 Expression
por: Zhang, Jing, et al.
Publicado: (2022)

SMARCD3 is a potential prognostic marker and therapeutic target in CAFs
por: Jiang, Ming, et al.
Publicado: (2020)

Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma
por: Ferguson, L. Paige, et al.
Publicado: (2023)

Tumor suppressive miR-99b-5p as an epigenomic regulator mediating mTOR/AR/SMARCD1 signaling axis in aggressive prostate cancer
por: Waseem, Mohammad, et al.
Publicado: (2023)

MBRS-63. THE ROLE OF THE SWI/SNF COMPLEX SUBUNIT SMARCD3 IN MEDULLOBLASTOMA
por: Poore, Brad, et al.
Publicado: (2020)

Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report
por: Nishimura, Hiroaki, et al.
Publicado: (2018)

Expression of SMARCD1 interacts with age in association with asthma control on inhaled corticosteroid therapy
por: McGeachie, Michael J., et al.
Publicado: (2020)

SMARCD1 negatively regulates myeloid differentiation of leukemic cells via epigenetic mechanisms
por: Saha, Subha, et al.
Publicado: (2022)

Smarcd1 Inhibits the Malignant Phenotypes of Human Glioblastoma Cells via Crosstalk with Notch1
por: Zhu, Yihao, et al.
Publicado: (2020)

Congenital Neutropenia with Specific Granulocyte Deficiency Caused by Novel Double Heterozygous SMARCD2 Mutations
por: Ibrahim, Abukhiran, et al.
Publicado: (2022)

LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling
por: Matsuda, R, et al.
Publicado: (2011)

Comprehensive analysis of the association of EGFR, CALM3 and SMARCD1 gene polymorphisms with BMD in Caucasian women
por: Zhou, Qiu-Hong, et al.
Publicado: (2014)

Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma
por: Hidaka, Hideo, et al.
Publicado: (2012)

Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer
por: Miyamoto, K, et al.
Publicado: (2016)

SWI/SNF Subunits SMARCA4, SMARCD2 and DPF2 Collaborate in MLL-Rearranged Leukaemia Maintenance
por: Cruickshank, V. Adam, et al.
Publicado: (2015)

Defective neutrophil development and specific granule deficiency caused by a homozygous splice-site mutation in SMARCD2
por: Schim van der Loeff, Ina, et al.
Publicado: (2021)

Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma
por: YAMASAKI, TAKESHI, et al.
Publicado: (2012)

A neurodevelopmental epigenetic programme mediated by SMARCD3–DAB1–Reelin signalling is hijacked to promote medulloblastoma metastasis
por: Zou, Han, et al.
Publicado: (2023)

The role of microRNAs in bladder cancer
por: Enokida, Hideki, et al.
Publicado: (2016)

Withdrawal: MicroRNA-7 compromises p53-dependent apoptosis by controlling the expression of the chromatin remodeling factor SMARCD1
por: Hong, Chun-Fu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rsv3gu2u4tjcbphierg7b8o52e